Influence of WHO versus ELN advanced phase chronic myeloid leukemia definitions on overall survival
Eur J Haematol
.
2017 Oct;99(4):381-382.
doi: 10.1111/ejh.12928.
Epub 2017 Aug 15.
Authors
Inge G P Geelen
1
,
Noortje Thielen
2
3
,
Jeroen J W M Janssen
2
,
Mark-David Levin
1
,
Mels Hoogendoorn
4
,
Otto Visser
5
,
Jan J Cornelissen
6
,
Peter E Westerweel
1
Affiliations
1
Department of Internal Medicine/Hematology, Albert Schweitzer Hospital, Dordrecht, the Netherlands.
2
Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands.
3
Department of Internal Medicine, Diakonessenhuis, Utrecht, the Netherlands.
4
Department of Hematology, Medical Center Leeuwarden, Leeuwarden, the Netherlands.
5
Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands.
6
Department of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands.
PMID:
28718971
DOI:
10.1111/ejh.12928
No abstract available
Publication types
Letter
Comment
MeSH terms
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*
Leukemia, Myeloid, Chronic-Phase
World Health Organization*
Substances
Imatinib Mesylate